Curis, Inc.

Curis develops emavusertib, an oral small molecule IRAK4 and FLT3 inhibitor in Phase 1/2 and Phase 2 studies for relapsed/refractory primary central nervous system lymphoma and chronic lymphocytic leukemia in combination with BTK inhibitors, and monotherapy studies in acute myeloid leukemia and myelodysplastic syndrome.